Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Olema Pharmaceuticals, Inc. (OLMA) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Olema Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1750284.
Total stock buying since 2020: $88,754,737.
Total stock sales since 2020: $71,049,351.
Total stock option exercises since 2020: $2,205,505.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 300,000 | $1,727,400 | 0 | $0 | 0 | $0 |
| 2024 | 700,761 | $4,730,136 | 4,640,686 | $61,680,127 | 132,160 | $847,869 |
| 2023 | 2,255,932 | $22,858,307 | 343,074 | $4,393,498 | 26,000 | $182,520 |
| 2022 | 200,000 | $807,000 | 10,504 | $60,920 | 15,755 | $32,518 |
| 2021 | 739,675 | $6,945,548 | 197,337 | $4,914,806 | 126,937 | $523,887 |
| 2020 | 2,720,334 | $51,686,346 | 0 | $0 | 135,525 | $618,711 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-01 | 300,000 | $1,727,400 | 0 | $0 | 0 | $0 |
| 2024-12 | 700,761 | $4,730,136 | 915,686 | $6,705,531 | 14,000 | $68,180 |
| 2024-11 | 0 | $0 | 0 | $0 | 25,000 | $175,500 |
| 2024-08 | 0 | $0 | 2,400,000 | $35,796,000 | 0 | $0 |
| 2024-07 | 0 | $0 | 10,000 | $139,171 | 0 | $0 |
| 2024-06 | 0 | $0 | 1,205,000 | $17,780,450 | 0 | $0 |
| 2024-05 | 0 | $0 | 20,000 | $195,750 | 9,460 | $46,070 |
| 2024-04 | 0 | $0 | 15,000 | $142,650 | 0 | $0 |
| 2024-03 | 0 | $0 | 20,000 | $219,400 | 13,700 | $66,719 |
| 2024-02 | 0 | $0 | 30,000 | $395,425 | 0 | $0 |
| 2024-01 | 0 | $0 | 25,000 | $305,750 | 70,000 | $491,400 |
| 2023-12 | 231,870 | $3,039,938 | 25,000 | $342,500 | 26,000 | $182,520 |
| 2023-11 | 0 | $0 | 153,074 | $2,184,299 | 0 | $0 |
| 2023-10 | 0 | $0 | 25,000 | $301,250 | 0 | $0 |
| 2023-09 | 2,014,062 | $19,818,369 | 105,000 | $1,300,349 | 0 | $0 |
| 2023-08 | 0 | $0 | 15,000 | $140,400 | 0 | $0 |
| 2023-06 | 0 | $0 | 20,000 | $124,700 | 0 | $0 |
| 2023-04 | 10,000 | $0 | 0 | $0 | 0 | $0 |
| 2022-06 | 200,000 | $807,000 | 0 | $0 | 0 | $0 |
| 2022-03 | 0 | $0 | 5,253 | $24,951 | 5,253 | $10,842 |
| 2022-02 | 0 | $0 | 0 | $0 | 5,251 | $10,838 |
| 2022-01 | 0 | $0 | 5,251 | $35,969 | 5,251 | $10,838 |
| 2021-12 | 0 | $0 | 15,251 | $157,557 | 5,251 | $10,838 |
| 2021-11 | 739,675 | $6,945,548 | 28,068 | $753,619 | 27,668 | $291,399 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-08 | Bain Capital Life Sciences Opportunities Iv, L.p. | Buy | 300,000 | 5.76 | 1,727,400 |
| 2024-12-17 | Graham G. Walmsley | Buy | 700,761 | 6.75 | 4,730,136 |
| 2024-12-17 | Graham G. Walmsley | Sale | 700,761 | 6.75 | 4,730,136 |
| 2024-12-16 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 14,000 | 4.87 | 68,180 |
| 2024-12-11 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Sale | 14,522 | 9.03 | 131,061 |
| 2024-12-11 | Harmon Cyrus | Sale | 8,137 | 9.03 | 73,436 |
| 2024-12-11 | Bohen Sean (PRESIDENT AND CEO) | Sale | 57,174 | 9.03 | 515,995 |
| 2024-12-11 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 13,614 | 9.03 | 122,866 |
| 2024-12-11 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Sale | 18,356 | 9.03 | 165,662 |
| 2024-12-10 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Sale | 13,283 | 9.37 | 124,461 |
| 2024-12-10 | Harmon Cyrus | Sale | 8,256 | 9.37 | 77,358 |
| 2024-12-10 | Bohen Sean (PRESIDENT AND CEO) | Sale | 52,328 | 9.37 | 490,313 |
| 2024-12-10 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 12,452 | 9.38 | 116,799 |
| 2024-12-10 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Sale | 16,803 | 9.37 | 157,444 |
| 2024-11-15 | Kovacs Shane William Charles (Ch. Operating & Financial Off.) | Option Ex | 25,000 | 7.02 | 175,500 |
| 2024-08-01 | Asefaw Senai | Sale | 2,400,000 | 14.91 | 35,796,000 |
| 2024-07-30 | Harmon Cyrus | Sale | 934 | 15.55 | 14,523 |
| 2024-07-29 | Harmon Cyrus | Sale | 4,066 | 15.58 | 63,348 |
| 2024-07-11 | Harmon Cyrus | Sale | 5,000 | 12.26 | 61,300 |
| 2024-06-28 | Harmon Cyrus | Sale | 20,000 | 10.77 | 215,400 |
| 2024-06-04 | Harmon Cyrus | Sale | 5,000 | 12.33 | 61,650 |
| 2024-06-04 | Graham G. Walmsley | Sale | 1,175,000 | 14.85 | 17,448,750 |
| 2024-06-03 | Harmon Cyrus | Sale | 5,000 | 10.93 | 54,650 |
| 2024-05-31 | Harmon Cyrus | Sale | 15,000 | 9.41 | 141,150 |
| 2024-05-24 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 9,460 | 4.87 | 46,070 |
| 2024-05-06 | Harmon Cyrus | Sale | 5,000 | 10.92 | 54,600 |
| 2024-04-30 | Harmon Cyrus | Sale | 15,000 | 9.51 | 142,650 |
| 2024-03-28 | Harmon Cyrus | Sale | 20,000 | 10.97 | 219,400 |
| 2024-03-18 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 13,700 | 4.87 | 66,719 |
| 2024-02-29 | Harmon Cyrus | Sale | 25,000 | 12.71 | 317,625 |
| 2024-02-01 | Harmon Cyrus | Sale | 5,000 | 15.56 | 77,800 |
| 2024-01-31 | Harmon Cyrus | Sale | 25,000 | 12.23 | 305,750 |
| 2024-01-25 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 20,000 | 7.02 | 140,400 |
| 2024-01-12 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Option Ex | 50,000 | 7.02 | 351,000 |
| 2023-12-29 | Harmon Cyrus | Sale | 25,000 | 13.70 | 342,500 |
| 2023-12-12 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Option Ex | 10,000 | 7.02 | 70,200 |
| 2023-12-11 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 2,900 | 7.02 | 20,358 |
| 2023-12-06 | Asefaw Senai | Buy | 100,000 | 11.60 | 1,160,000 |
| 2023-12-06 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Option Ex | 13,100 | 7.02 | 91,962 |
| 2023-12-05 | Graham G. Walmsley | Buy | 131,870 | 14.26 | 1,879,938 |
| 2023-11-30 | Harmon Cyrus | Sale | 25,000 | 12.57 | 314,250 |
| 2023-11-22 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Sale | 7,095 | 13.89 | 98,549 |
| 2023-11-22 | Harmon Cyrus | Sale | 3,989 | 13.90 | 55,447 |
| 2023-11-22 | Bohen Sean (PRESIDENT AND CEO) | Sale | 27,932 | 13.90 | 388,254 |
| 2023-11-22 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 6,653 | 13.89 | 92,410 |
| 2023-11-22 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Sale | 9,145 | 13.89 | 127,024 |
| 2023-11-21 | Zojwalla Naseem (CHIEF MEDICAL OFFICER) | Sale | 7,461 | 15.08 | 112,511 |
| 2023-11-21 | Harmon Cyrus | Sale | 4,192 | 14.86 | 62,293 |
| 2023-11-21 | Bohen Sean (PRESIDENT AND CEO) | Sale | 29,293 | 15.06 | 441,299 |
| 2023-11-21 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 6,976 | 15.10 | 105,302 |
| 2023-11-21 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Sale | 9,597 | 15.05 | 144,434 |
| 2023-11-08 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 200 | 17.61 | 3,522 |
| 2023-11-03 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 541 | 17.51 | 9,472 |
| 2023-11-02 | Harmon Cyrus | Sale | 5,000 | 15.64 | 78,200 |
| 2023-11-02 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 3,332 | 15.36 | 51,179 |
| 2023-11-01 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 6,668 | 15.02 | 100,153 |
| 2023-10-31 | Harmon Cyrus | Sale | 25,000 | 12.05 | 301,250 |
| 2023-09-29 | Harmon Cyrus | Sale | 50,000 | 12.41 | 620,500 |
| 2023-09-19 | Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) | Sale | 20,000 | 12.67 | 253,400 |
| 2023-09-12 | Graham G. Walmsley | Buy | 508,130 | 9.84 | 4,999,999 |
| 2023-09-12 | Lampert Mark N | Buy | 1,505,932 | 9.84 | 14,818,370 |
| 2023-09-05 | Harmon Cyrus | Sale | 10,000 | 11.62 | 116,199 |
| 2023-08-31 | Harmon Cyrus | Sale | 15,000 | 9.36 | 140,400 |
| 2023-06-08 | Harmon Cyrus | Sale | 10,000 | 6.30 | 63,000 |
| 2023-06-06 | Harmon Cyrus | Sale | 5,000 | 6.29 | 31,475 |
| 2023-06-05 | Harmon Cyrus | Sale | 5,000 | 6.04 | 30,225 |
| 2023-04-06 | Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) | Buy | 10,000 | .00 | 0 |
| 2022-06-10 | Lampert Mark N | Buy | 200,000 | 4.04 | 807,000 |
| 2022-03-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,253 | 4.75 | 24,951 |
| 2022-03-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,253 | 2.06 | 10,842 |
| 2022-02-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2022-01-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 6.85 | 35,969 |
| 2022-01-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-12-10 | Myles David C. (CHIEF DEVELOPMENT OFFICER) | Sale | 10,000 | 10.30 | 103,000 |
| 2021-12-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 10.39 | 54,557 |
| 2021-12-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-11-30 | Lampert Mark N | Buy | 739,675 | 9.39 | 6,945,548 |
| 2021-11-29 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 400 | 24.76 | 9,904 |
| 2021-11-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 27,668 | 26.88 | 743,715 |
| 2021-11-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 27,668 | 10.53 | 291,399 |
| 2021-10-19 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 12,000 | 28.02 | 336,300 |
| 2021-10-14 | Bohen Sean (PRESIDENT AND CEO) | Sale | 5,000 | 30.80 | 153,975 |
| 2021-10-14 | Bohen Sean (PRESIDENT AND CEO) | Option Ex | 5,000 | 4.82 | 24,120 |
| 2021-10-11 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 27.83 | 146,135 |
| 2021-10-11 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-09-27 | Bohen Sean (PRESIDENT AND CEO) | Sale | 1,085 | 30.07 | 32,625 |
| 2021-09-27 | Bohen Sean (PRESIDENT AND CEO) | Option Ex | 1,085 | 4.82 | 5,234 |
| 2021-09-20 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 12,000 | 26.30 | 315,600 |
| 2021-09-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 29.38 | 154,274 |
| 2021-09-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-09-08 | Bohen Sean (PRESIDENT AND CEO) | Sale | 2,631 | 30.00 | 78,930 |
| 2021-09-08 | Bohen Sean (PRESIDENT AND CEO) | Option Ex | 2,631 | 4.82 | 12,691 |
| 2021-09-07 | Bohen Sean (PRESIDENT AND CEO) | Sale | 413 | 30.08 | 12,423 |
| 2021-09-07 | Bohen Sean (PRESIDENT AND CEO) | Option Ex | 413 | 4.82 | 1,992 |
| 2021-09-01 | Bohen Sean (PRESIDENT AND CEO) | Sale | 871 | 30.05 | 26,173 |
| 2021-09-01 | Bohen Sean (PRESIDENT AND CEO) | Option Ex | 871 | 4.82 | 4,201 |
| 2021-08-19 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 12,000 | 24.97 | 299,640 |
| 2021-08-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 25.93 | 136,184 |
| 2021-08-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-07-20 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 4,123 | 25.63 | 105,672 |
| 2021-07-19 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 7,877 | 24.83 | 195,585 |
| 2021-07-12 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 26.66 | 140,017 |
| 2021-07-12 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-06-18 | Harmon Cyrus (CHIEF TECHNOLOGY OFFICER) | Sale | 12,000 | 25.48 | 305,724 |
| 2021-06-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 5,251 | 29.29 | 153,801 |
| 2021-06-10 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 5,251 | 2.06 | 10,838 |
| 2021-05-18 | Horn Kinney (CHIEF BUSINESS OFFICER) | Sale | 57,763 | 24.42 | 1,410,572 |
| 2021-05-18 | Horn Kinney (CHIEF BUSINESS OFFICER) | Option Ex | 57,763 | 2.06 | 119,222 |
| 2020-11-23 | Cormorant Private Healthcare Fund Iii Lp | Buy | 425,000 | 19.00 | 8,075,000 |
| 2020-11-23 | Graham G. Walmsley (Director) | Buy | 1,160,000 | 19.00 | 22,040,000 |
| 2020-11-19 | Lampert Mark N | Buy | 1,135,334 | 19.00 | 21,571,346 |
| 2020-09-23 | Bohen Sean (President and CEO) | Option Ex | 51,649 | 4.82 | 249,154 |
| 2020-09-16 | Butitta Cynthia M (Director) | Option Ex | 83,876 | 4.41 | 369,557 |
Insider trading activities including stock purchases, stock sales, and option exercises of OLMA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Olema Pharmaceuticals, Inc. (symbol OLMA, CIK number 1750284) see the Securities and Exchange Commission (SEC) website.